Pub Date : 2024-07-13DOI: 10.1134/S1607672924700996
D. A. Dibrov, A. S. Avdeeva, V. V. Rybakova, N. V. Demidova, E. L. Nasonov
The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of rheumatoid arthritis.
The study included patients with a reliable diagnosis of rheumatoid arthritis (RA) according to the criteria of ACR/EULAR 2010. Depending on the ACPA values, two groups of patients were recruited: ACPA-positive and ACPA-negative, comparable in gender, age, duration of the disease, and therapy. The nature of the onset and course of the disease and the activity of RA were evaluated (according to the DAS28, SDAI, CDAI indices).
The study involved 79 patients with ACPA-negative variant of RA and 79 ACPA-positive patients. The age of patients (Me [IR] (in years)) with the ACPA(–) variant was 52 [39; 62]; with the ACPA(+) variant, 54 [42; 62]; the duration of the disease (in months) was 59 [23; 122] and 48 [17; 84], respectively.
In ACPA(+) patients, a higher disease activity was determined (by the indices DAS 28crp, DAS28esr, SDAI, CDAI), higher values of C-reactive protein and erythrocyte sedimentation rate, and a greater number of painful and swollen joints (p < 0.05).
According to the localization of the involved joints, arthritis of the proximal interphalangeal, metacarpal, wrist and shoulder joints was more often determined in ACPA(+) patients.
Systemic manifestations of RA at the time of examination and in the anamnesis were statistically significantly more common in ACPA(+) (32.9%) than in ACPA(–) (17.7%) patients. Of the systemic manifestations, rheumatoid nodules were more common in ACPA(+) patients, whereas a tendency to a higher frequency of neuropathy, sclerites, and episcleritis was revealed in ACPA(–) patients.
. In patients with ACPA(–) subtype, clinical signs of joint damage and the inflammatory component are less pronounced compared to ACPA(+). However, the mixed picture of manifestation, the less “bright” course of the disease, the absence of characteristic immunological biomarkers necessitate long-term and careful monitoring of this group of patients. At the same time, the subjective severity of the disease and dysfunction due to ankylosing joints do not differ from the ACPA(+) variant of RA.
该研究的目的是调查 ACPA 阴性和 ACPA 阳性变异型类风湿性关节炎患者的临床表现特征:研究对象包括根据 ACR/EULAR 2010 标准确诊为类风湿性关节炎(RA)的患者。根据 ACPA 值,招募了两组患者:ACPA阳性和ACPA阴性两组患者在性别、年龄、病程和治疗方面具有可比性。根据 DAS28、SDAI、CDAI 指数,对发病性质、病程和 RA 活动性进行了评估:研究涉及 79 名 ACPA 阴性变异型 RA 患者和 79 名 ACPA 阳性患者。ACPA(-)变异型患者的年龄(Me[IR](单位:岁))为52[39;62];ACPA(+)变异型患者的年龄(Me[IR](单位:岁))为54[42;62];病程(单位:月)分别为59[23;122]和48[17;84]。ACPA(+)患者的疾病活动度较高(通过 DAS 28crp、DAS 28esr、SDAI、CDAI 等指数),C 反应蛋白和红细胞沉降率的数值较高,关节疼痛和肿胀的数量较多(P < 0.05)。从受累关节的部位来看,ACPA(+)患者的关节炎多见于近端指间关节、掌指关节、腕关节和肩关节。据统计,ACPA(+)患者在检查时和病史中出现全身性 RA 表现的比例(32.9%)明显高于 ACPA(-)患者(17.7%)。在全身表现中,类风湿结节在 ACPA(+)患者中更为常见,而在 ACPA(-)患者中,神经病变、硬结和上皮炎的发病率则呈上升趋势。结论:在 ACPA(-)亚型患者中,关节损伤和炎症成分的临床表现不如 ACPA(+)明显。然而,由于表现不一、病程不太 "光明"、缺乏特征性免疫生物标志物,因此有必要对这部分患者进行长期、仔细的监测。同时,疾病的主观严重程度和强直性关节引起的功能障碍与ACPA(+)变异型RA并无不同。
{"title":"Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis","authors":"D. A. Dibrov, A. S. Avdeeva, V. V. Rybakova, N. V. Demidova, E. L. Nasonov","doi":"10.1134/S1607672924700996","DOIUrl":"10.1134/S1607672924700996","url":null,"abstract":"<p>The aim of the study was to investigate the features of the clinical picture of the disease in patients with ACPA–negative and ACPA-positive variants of rheumatoid arthritis.</p><p>The study included patients with a reliable diagnosis of rheumatoid arthritis (RA) according to the criteria of ACR/EULAR 2010. Depending on the ACPA values, two groups of patients were recruited: ACPA-positive and ACPA-negative, comparable in gender, age, duration of the disease, and therapy. The nature of the onset and course of the disease and the activity of RA were evaluated (according to the DAS28, SDAI, CDAI indices).</p><p>The study involved 79 patients with ACPA-negative variant of RA and 79 ACPA-positive patients. The age of patients (Me [IR] (in years)) with the ACPA(–) variant was 52 [39; 62]; with the ACPA(+) variant, 54 [42; 62]; the duration of the disease (in months) was 59 [23; 122] and 48 [17; 84], respectively.</p><p>In ACPA(+) patients, a higher disease activity was determined (by the indices DAS 28crp, DAS28esr, SDAI, CDAI), higher values of C-reactive protein and erythrocyte sedimentation rate, and a greater number of painful and swollen joints (<i>p</i> < 0.05).</p><p>According to the localization of the involved joints, arthritis of the proximal interphalangeal, metacarpal, wrist and shoulder joints was more often determined in ACPA(+) patients.</p><p>Systemic manifestations of RA at the time of examination and in the anamnesis were statistically significantly more common in ACPA(+) (32.9%) than in ACPA(–) (17.7%) patients. Of the systemic manifestations, rheumatoid nodules were more common in ACPA(+) patients, whereas a tendency to a higher frequency of neuropathy, sclerites, and episcleritis was revealed in ACPA(–) patients.</p><p><b>.</b> In patients with ACPA(–) subtype, clinical signs of joint damage and the inflammatory component are less pronounced compared to ACPA(+). However, the mixed picture of manifestation, the less “bright” course of the disease, the absence of characteristic immunological biomarkers necessitate long-term and careful monitoring of this group of patients. At the same time, the subjective severity of the disease and dysfunction due to ankylosing joints do not differ from the ACPA(+) variant of RA.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141603160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S160767292470100X
Yu. Yu. Dgebuadze, N. N. Sushchik, B. Mendsaikhan, D. Altansukh, A. Y. Emelianova, M. I. Gladyshev
The composition of fatty acids in the muscle tissue of the unique Central Asian carp-like fish, Potanin Altai osman Oreoleuciscus potanini, was studied for the first time. The populations of these fish in the reservoirs of the semiarid zone (Durgun and Taishir) during the period of their formation are considered. It was shown that the content of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids in O. potanini corresponds to the median of this value in the order Cypriniformes. It was established that the basis of the food web of the herbivorous form of this species consists of microalgae (diatoms, Euglena and, possibly, chrysophytes), as well as bacteria. At the same time, the levels of bacterial biomarkers, 15-17BCFA and 17:0 were significantly higher in fish in the Durgun reservoir, whereas the level of EPA (diatom biomarker) in O. potanini was higher in the Taishir reservoir. The established higher values of the heavy nitrogen isotope content in the muscles of O. potanini from the Taishir reservoir are most likely associated with the yet unformed benthic communities and with the incomplete diversification of the riverine form of the Potanin Altai osman into lacustrine forms.
首次研究了中亚独特的鲤科鱼类 Potanin Altai osman Oreoleuciscus potanini 肌肉组织中的脂肪酸组成。研究考虑了半干旱地区(杜尔贡和塔希尔)水库中这些鱼类形成时期的种群数量。研究表明,O. potanini 中的二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)含量与鲤形目中这一数值的中位数一致。研究结果表明,该物种草食性食物网的基础是微藻(硅藻、八角藻,可能还有菊叶藻)和细菌。同时,杜尔贡水库中鱼类的细菌生物标志物、15-17BCFA 和 17:0 的含量明显较高,而塔希尔水库中 O. potanini 的 EPA(硅藻生物标志物)含量较高。塔依什尔水库中的 O. potanini 肌肉重氮同位素含量较高,这很可能与尚未形成的底栖生物群落有关,也与波坦宁阿尔泰鄂温克人的河流形态未完全分化为湖泊形态有关。
{"title":"Composition and Content of Fatty Acids in Muscle Tissue of the Potanin Altai Osman Oreoleuciscus potanini (Cypriniformes, Actinopterigii) from Mongolian Reservoirs","authors":"Yu. Yu. Dgebuadze, N. N. Sushchik, B. Mendsaikhan, D. Altansukh, A. Y. Emelianova, M. I. Gladyshev","doi":"10.1134/S160767292470100X","DOIUrl":"10.1134/S160767292470100X","url":null,"abstract":"<p>The composition of fatty acids in the muscle tissue of the unique Central Asian carp-like fish, Potanin Altai osman <i>Oreoleuciscus potanini</i>, was studied for the first time. The populations of these fish in the reservoirs of the semiarid zone (Durgun and Taishir) during the period of their formation are considered. It was shown that the content of eicosapentaenoic (EPA) and docosahexaenoic (DHA) acids in <i>O. potanini</i> corresponds to the median of this value in the order Cypriniformes. It was established that the basis of the food web of the herbivorous form of this species consists of microalgae (diatoms, <i>Euglena</i> and, possibly, chrysophytes), as well as bacteria. At the same time, the levels of bacterial biomarkers, 15-17BCFA and 17:0 were significantly higher in fish in the Durgun reservoir, whereas the level of EPA (diatom biomarker) in <i>O. potanini</i> was higher in the Taishir reservoir. The established higher values of the heavy nitrogen isotope content in the muscles of <i>O. potanini</i> from the Taishir reservoir are most likely associated with the yet unformed benthic communities and with the incomplete diversification of the riverine form of the Potanin Altai osman into lacustrine forms.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S1607672924701047
A. Yu. Ryss
Fundamental aspects in the evolution of nematodes parasitizing woody plants are reviewed. (1) Nematode faunal lists of natural refugia are useful to predict the risks of opportunistic pathogens becoming true pathogens in the forest and park communities. (2) Nematode composition in natural refugia gives a chance to identify nematode antagonists of insect vectors of dangerous fungal and nematode infections, which can be potentially used as the biological agents for woody plants’ protection. (3) Dauers in the ancestors of wood-inhabiting nematodes played a role as a survival stage in the detritus decomposition succession, and they later acquired the functions of dispersal and adaptations for transmission using insect vectors. (4) When inspecting wilted trees, it is necessary to use dauers for diagnostics, as sexually mature nematodes may be absent in tree tissues. (5) Plant parasitic nematodes originated from members of the detritus food web and retained a detritivorous phase in the life cycle as a part of the propagative generation. (6) Vectors in the life cycles of plant parasitic nematodes are inherited from the ancestral detritivorous nematode associations, rather than inserted in the dixenic life cycle of the ‘nematode–fungus–plant’ association. (7) Despite the significant difference in the duration of the nematode–tree and nematode–vector phases of the life cycle, the actual parasitic nematode specificity is dual: firstly to the vector and secondly to the natural host plant (as demonstrated in phytotests excluding a vector).
{"title":"Evolution of Life Cycles of Nematodes Parasitizing Woody Plants As a Result of Ecological and Phylogenetic Co-Adaptations with Hosts and Vectors","authors":"A. Yu. Ryss","doi":"10.1134/S1607672924701047","DOIUrl":"10.1134/S1607672924701047","url":null,"abstract":"<p>Fundamental aspects in the evolution of nematodes parasitizing woody plants are reviewed. (1) Nematode faunal lists of natural refugia are useful to predict the risks of opportunistic pathogens becoming true pathogens in the forest and park communities. (2) Nematode composition in natural refugia gives a chance to identify nematode antagonists of insect vectors of dangerous fungal and nematode infections, which can be potentially used as the biological agents for woody plants’ protection. (3) Dauers in the ancestors of wood-inhabiting nematodes played a role as a survival stage in the detritus decomposition succession, and they later acquired the functions of dispersal and adaptations for transmission using insect vectors. (4) When inspecting wilted trees, it is necessary to use dauers for diagnostics, as sexually mature nematodes may be absent in tree tissues. (5) Plant parasitic nematodes originated from members of the detritus food web and retained a detritivorous phase in the life cycle as a part of the propagative generation. (6) Vectors in the life cycles of plant parasitic nematodes are inherited from the ancestral detritivorous nematode associations, rather than inserted in the dixenic life cycle of the ‘nematode–fungus–plant’ association. (7) Despite the significant difference in the duration of the nematode–tree and nematode–vector phases of the life cycle, the actual parasitic nematode specificity is dual: firstly to the vector and secondly to the natural host plant (as demonstrated in phytotests excluding a vector).</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S1607672924701059
P. A. Smirnov, D. Yu. Krupenko
We performed a detailed ultrastructural reconstruction of the “passive” miracidium of Derogenes varicus Muller, 1784 , a species from the Hemiurata group. The miracidium is highly miniaturized and simplified in comparison with the “active” miracidia. For the first time we elucidated the nature of the spines on the surface of the hemiuroid larva: they are derivatives of the epithelial plates. The anterior end of the larva is equipped with three epithelial plates that bear both spines and cilia. The major part of the miracidial surface is formed by the tegument. The nervous and excretory systems of the D. varicus miracidium are extremely reduced. Single undifferentiated cell comprises the germinal material of the miracidium. We discuss the trends of evolution of hemiuroid miracidia that are associated with the transition to passive strategy of infection.
{"title":"Reconstruction of Derogenes varicus Miracidium (Digenea: Derogenidae): First Ultrastructural Description of Spines on the Surface of Hemiurata Larvae","authors":"P. A. Smirnov, D. Yu. Krupenko","doi":"10.1134/S1607672924701059","DOIUrl":"10.1134/S1607672924701059","url":null,"abstract":"<p>We performed a detailed ultrastructural reconstruction of the “passive” miracidium of <i>Derogenes varicus</i> Muller, 1784 , a species from the Hemiurata group. The miracidium is highly miniaturized and simplified in comparison with the “active” miracidia. For the first time we elucidated the nature of the spines on the surface of the hemiuroid larva: they are derivatives of the epithelial plates. The anterior end of the larva is equipped with three epithelial plates that bear both spines and cilia. The major part of the miracidial surface is formed by the tegument. The nervous and excretory systems of the <i>D. varicus</i> miracidium are extremely reduced. Single undifferentiated cell comprises the germinal material of the miracidium. We discuss the trends of evolution of hemiuroid miracidia that are associated with the transition to passive strategy of infection.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S1607672924701060
A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Y. D. Kurochkina, Y. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev
<p>The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (biological DMARDs, or biologics) on the course and outcomes of a new coronavirus infection. A number of studies have shown that anti-B-cell therapy (rituximab) gave a statistically significant increase in the risk of severe COVID-19 and an increase in mortality. At the same time, the analysis of real clinical practice data dictated the need to establish a number of restrictions on the use of certain classes of biologics and to search for alternative therapy programs to maintain control over disease activity.</p><p><b>Purpose of the study.</b> The purpose of the study was to evaluate the efficacy and safety of the drug Artlegia® (olokizumab), solution for subcutaneous injection, 160 mg/ml-0.4 ml, manufactured by R-Pharm JSC, Russia) for the treatment of patients with rheumatoid arthritis in real clinical practice after switching with rituximab during the COVID-19 pandemic.</p><p><b>Materials and methods.</b> The study included 14 patients with a confirmed diagnosis of rheumatoid arthritis (RA), who were previously on rituximab therapy at a dose of 1000–500 mg twice with an interval of 2 weeks, who received at least one course of therapy with this drug. As RA worsened, patients were switched to olokizumab against the background of standard DMARDs. On weeks 0, 4, 8, and 12 after the switch, the severity of pain was assessed on the VAS scale, the number of tender and swollen joints (TJC28 and SJC28), the level of acute-phase inflammation markers, the DAS28 (disease activity score), ESR, CRP, CDAI (clinical activity index), and the functional state index HAQ (Health Assessment Questionnaire) were determined, as well as the safety profile of therapy was assessed.</p><p><b>Results.</b> Data analysis was performed using median values (Me) were used for data analysis. A significant decrease in TJC28 was detected after 8 and 12 weeks of treatment with olokizumab (Artlegia®) (Me baseline = 10, Me 8 weeks = 4, Me 12 weeks = 4, <i>p</i> < 0.05) and a decrease in TSC28 was detected after 4, 8, and 12 weeks of treatment (Me baseline = 9, Me 4 weeks = 3.5, Me 8 weeks = 2.5, Me 12 weeks = 2.0, <i>p</i> < 0.05). Laboratory markers of inflammation showed a decrease in CRP and ESR levels after 4 weeks of treatment (CRP: Me4 weeks = 21, Me4 weeks = 1, <i>p</i> < 0.05, ESR: Mesno = 31, Me4 weeks = 7, <i>p</i> < 0.05). Positive dynamics persisted on 8 and 12 weeks (CRP: Me 8 weeks = 1, Me 12 weeks = 0; ESR: Me 8 weeks = 4, Me 12 weeks = 5). The level of CRP by week 4 became within the normal range, regardless of the initial values. All activity indices improved from week 4 in each evaluation period compared to baseline: DAS28-ESR: Me baseline = 5.52,
{"title":"Results of a 12-Week Open-Label, Non-Interventional Study of the Efficacy and Safety of Olokizumab Therapy in Patients with Rheumatoid Arthritis after Switching from Anti-B-Cell Therapy during the SARS-CoV-2 Pandemic","authors":"A. A. Akimova, N. E. Banshchikova, A. E. Sizikov, A. A. Mullagaliev, E. A. Letyagina, N. A. Ilina, Y. D. Kurochkina, Y. B. Ubshaeva, V. O. Omelchenko, O. A. Chumasova, N. S. Shkaruba, M. A. Korolev","doi":"10.1134/S1607672924701060","DOIUrl":"10.1134/S1607672924701060","url":null,"abstract":"<p>The COVID-19 pandemic has significantly changed the understanding of the safety profile of therapies for immunoinflammatory rheumatic diseases (IRDs). This is primarily due to the negative impact of a number of basic disease-modifying antirheumatic drugs (DMARDs) and genetically engineered biological drugs (biological DMARDs, or biologics) on the course and outcomes of a new coronavirus infection. A number of studies have shown that anti-B-cell therapy (rituximab) gave a statistically significant increase in the risk of severe COVID-19 and an increase in mortality. At the same time, the analysis of real clinical practice data dictated the need to establish a number of restrictions on the use of certain classes of biologics and to search for alternative therapy programs to maintain control over disease activity.</p><p><b>Purpose of the study.</b> The purpose of the study was to evaluate the efficacy and safety of the drug Artlegia® (olokizumab), solution for subcutaneous injection, 160 mg/ml-0.4 ml, manufactured by R-Pharm JSC, Russia) for the treatment of patients with rheumatoid arthritis in real clinical practice after switching with rituximab during the COVID-19 pandemic.</p><p><b>Materials and methods.</b> The study included 14 patients with a confirmed diagnosis of rheumatoid arthritis (RA), who were previously on rituximab therapy at a dose of 1000–500 mg twice with an interval of 2 weeks, who received at least one course of therapy with this drug. As RA worsened, patients were switched to olokizumab against the background of standard DMARDs. On weeks 0, 4, 8, and 12 after the switch, the severity of pain was assessed on the VAS scale, the number of tender and swollen joints (TJC28 and SJC28), the level of acute-phase inflammation markers, the DAS28 (disease activity score), ESR, CRP, CDAI (clinical activity index), and the functional state index HAQ (Health Assessment Questionnaire) were determined, as well as the safety profile of therapy was assessed.</p><p><b>Results.</b> Data analysis was performed using median values (Me) were used for data analysis. A significant decrease in TJC28 was detected after 8 and 12 weeks of treatment with olokizumab (Artlegia®) (Me baseline = 10, Me 8 weeks = 4, Me 12 weeks = 4, <i>p</i> < 0.05) and a decrease in TSC28 was detected after 4, 8, and 12 weeks of treatment (Me baseline = 9, Me 4 weeks = 3.5, Me 8 weeks = 2.5, Me 12 weeks = 2.0, <i>p</i> < 0.05). Laboratory markers of inflammation showed a decrease in CRP and ESR levels after 4 weeks of treatment (CRP: Me4 weeks = 21, Me4 weeks = 1, <i>p</i> < 0.05, ESR: Mesno = 31, Me4 weeks = 7, <i>p</i> < 0.05). Positive dynamics persisted on 8 and 12 weeks (CRP: Me 8 weeks = 1, Me 12 weeks = 0; ESR: Me 8 weeks = 4, Me 12 weeks = 5). The level of CRP by week 4 became within the normal range, regardless of the initial values. All activity indices improved from week 4 in each evaluation period compared to baseline: DAS28-ESR: Me baseline = 5.52, ","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S1607672924701023
V. P. Nikishin, D. V. Ponomarev
The giant tegument nuclei of the acanthocephalans of the classes Archiacanthocephala and Palaeacanthocephala are fragmented at the final stage of cystacanthus formation in the intermediate host, but remain connected with each other during later life. It can be assumed that the fragments of each giant tegument nucleus are united with each other to form an independent network that ensures the vital activity of the tegument, the volume of which increases many times during the period of intensive growth of the parasite in the definitive host.
{"title":"Organization of the Nuclei in the Tegument of Some Palaeacanthocephala and Archiacanthocephala","authors":"V. P. Nikishin, D. V. Ponomarev","doi":"10.1134/S1607672924701023","DOIUrl":"10.1134/S1607672924701023","url":null,"abstract":"<p>The giant tegument nuclei of the acanthocephalans of the classes Archiacanthocephala and Palaeacanthocephala are fragmented at the final stage of cystacanthus formation in the intermediate host, but remain connected with each other during later life. It can be assumed that the fragments of each giant tegument nucleus are united with each other to form an independent network that ensures the vital activity of the tegument, the volume of which increases many times during the period of intensive growth of the parasite in the definitive host.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S1607672924701035
K. V. Regel
Metacestode infestation of Semibalanus balanoides (L., 1767) and Balanus crenatus Bruguiеre, 1789, collected in the Barents and White Seas and in the northern part of the Sea of Okhotsk in 2020 and 2021, respectively, was studied. A total of 313 S. balanoides from Mogilnaya Bay of Kildin Island (Barents Sea) and isolated mature wrinkled barnacles B. crenatus, two and four specimens from the Pechora Sea and Kandalaksha Bay of the White Sea, respectively, were examined in 2020. Metacestodes Fimbriarioides intermedia (Fuhrmann, 1913) (Cyclophyllidea, Hymenolepididae) were found in 1.0 ± 0.6% of S. balanoides in the Barents Sea with an invasion intensity (I. I.) of 2–5 specimens, and in one of two B. crenatus from the Pechora Sea (I. I. 15 specimens). For the first time, in both B. crenatus from the Pechora Sea, taken from the valves of the mussel Mytilus edulis, metacestodes Microsomacanthus sp. I (I. I. 13 and 20 specimens) with proboscis hooks 38–41 (39.4 ± 0.1) µm long and blades of 9.5–11 (10.7 ± 0.1) µm were obtained. One of four B. crenatus from the Kandalaksha Bay was infected with another Microsomacanthus sp. II (I. I. 19 specimens) with proboscis hooks 44.0–49.5 (45.7 ± 0.5) µm long and blades 14.0–16.0 (14.8 ± 0.07) µm long. A total of 362 S. balanoides were collected and dissected in Gizhiginskaya Bay of the northern part of the Sea of Okhotsk in 2021, of which 8.0 ± 1.4% were infected with F. intermedia metacestodes (I. I. 1–19 specimens). Study results of the infestation of S. balanoides on the Koni-Pyagin coast of the Sea of Okhotsk (according to the collections of 2006–2007) were supplemented and clarified. Description of metacestodes and the taxonomic affiliation of cysticercoids Microsomacanthus spp. are given.
研究了分别于 2020 年和 2021 年在巴伦支海和白海以及鄂霍次克海北部采集的 Semibalanus balanoides (L., 1767) 和 Balanus crenatus Bruguiеre, 1789 的元虫侵染情况。2020 年,研究人员对来自基尔丁岛(巴伦支海)莫吉尔纳亚湾的 313 个 S. balanoides 和分离出的成熟皱纹藤壶 B. crenatus(分别来自佩乔拉海和白海坎达拉沙湾的 2 个和 4 个标本)进行了研究。在巴伦支海 1.0 ± 0.6% 的 S. balanoides(入侵强度 (I. I.) 为 2-5 个标本)和佩乔拉海两个 B. crenatus(入侵强度 (I. I.) 为 15 个标本)中的一个中发现了介壳虫 Fimbriarioides intermedia (Fuhrmann, 1913) (Cyclophyllidea, Hymenolepididae)。在佩乔拉海的两只 B. crenatus(取自 Mytilus edulis 的贻贝瓣膜)中,首次发现了元绦虫 Microsomacanthus sp. I(I. I. 13 和 20 个标本),其探针钩长 38-41 (39.4 ± 0.1) µm,叶片长 9.5-11 (10.7 ± 0.1) µm。坎达拉克沙湾的四条 B. crenatus 中,有一条感染了另一种 Microsomacanthus sp. II(I. I. 19 标本),其探针钩长 44.0-49.5 (45.7 ± 0.5) µm,叶片长 14.0-16.0 (14.8 ± 0.07) µm。2021 年,在鄂霍次克海北部的吉日金斯卡亚湾共采集并解剖了 362 条 S. balanoides,其中 8.0 ± 1.4% 感染了 F. intermedia metacestodes(I. I. 1-19 标本)。补充并澄清了鄂霍次克海科尼-皮亚金海岸 S. balanoides 侵染的研究结果(根据 2006-2007 年的采集结果)。此外,还给出了元绦虫的描述以及囊尾蚴属(Microsomacanthus spp.)的分类归属。
{"title":"Semibalanus balanoides (L.) and Balanus crenatus Bruguière (Balanidae) Are Intermediate Hosts of Fimbriarioides intermedia (Fuhrmann, 1913) and Two Species of the Genus Microsomacanthus (Cestoda: Hymenolepidae), Parasites of Sea Ducks from the Atlantic Sector of the Arctic and Northern Pacific","authors":"K. V. Regel","doi":"10.1134/S1607672924701035","DOIUrl":"10.1134/S1607672924701035","url":null,"abstract":"<p>Metacestode infestation of <i>Semibalanus balanoides</i> (L., 1767) and <i>Balanus crenatus</i> Bruguiеre, 1789, collected in the Barents and White Seas and in the northern part of the Sea of Okhotsk in 2020 and 2021, respectively, was studied. A total of 313 <i>S. balanoides</i> from Mogilnaya Bay of Kildin Island (Barents Sea) and isolated mature wrinkled barnacles <i>B. crenatus</i>, two and four specimens from the Pechora Sea and Kandalaksha Bay of the White Sea, respectively, were examined in 2020. Metacestodes <i>Fimbriarioides intermedia</i> (Fuhrmann, 1913) (Cyclophyllidea, Hymenolepididae) were found in 1.0 ± 0.6% of <i>S. balanoides</i> in the Barents Sea with an invasion intensity (I. I.) of 2–5 specimens, and in one of two <i>B. crenatus</i> from the Pechora Sea (I. I. 15 specimens). For the first time, in both <i>B. crenatus</i> from the Pechora Sea, taken from the valves of the mussel <i>Mytilus edulis</i>, metacestodes <i>Microsomacanthus</i> sp. I (I. I. 13 and 20 specimens) with proboscis hooks 38–41 (39.4 ± 0.1) µm long and blades of 9.5–11 (10.7 ± 0.1) µm were obtained. One of four <i>B. crenatus</i> from the Kandalaksha Bay was infected with another <i>Microsomacanthus</i> sp. II (I. I. 19 specimens) with proboscis hooks 44.0–49.5 (45.7 ± 0.5) µm long and blades 14.0–16.0 (14.8 ± 0.07) µm long. A total of 362 <i>S. balanoides</i> were collected and dissected in Gizhiginskaya Bay of the northern part of the Sea of Okhotsk in 2021, of which 8.0 ± 1.4% were infected with <i>F. intermedia</i> metacestodes (I. I. 1–19 specimens). Study results of the infestation of <i>S. balanoides</i> on the Koni-Pyagin coast of the Sea of Okhotsk (according to the collections of 2006–2007) were supplemented and clarified. Description of metacestodes and the taxonomic affiliation of cysticercoids <i>Microsomacanthus</i> spp. are given.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-07-01DOI: 10.1134/S1607672924701011
O. A. Loginova, S. E. Spiridonov, O. V. Maslennikova, L. A. Bukina
This work presents the results of studying the molecular characteristics of parasitic tapeworms Echinococcus canadensis. The helminths were discovered during the autopsy of a wolf (Canis lupus Linnaeus, 1758) killed by hunters in the Kirov oblast in 2021. A molecular phylogenetic study was performed by analyzing the sequence of a fragment of the first subunit of the mitochondrial cytochrome oxidase gene (CoxI). It was found that the detected echinococci belong to the G10 genotype of E. canadensis, which is common in wolves in the northern territories of the Holarctic. We discovered four positions at which the substitutions characteristic only of this genotype are revealed. A substitution at one of the positions that is characteristic exclusively for the representatives of the G10 genotype found in Russia and Finland was also discovered.
{"title":"Molecular Characterization of Echinococcus canadensis (Cestoda, Taeniidae) in Wolf from the Kirov Region","authors":"O. A. Loginova, S. E. Spiridonov, O. V. Maslennikova, L. A. Bukina","doi":"10.1134/S1607672924701011","DOIUrl":"10.1134/S1607672924701011","url":null,"abstract":"<p>This work presents the results of studying the molecular characteristics of parasitic tapeworms <i>Echinococcus canadensis</i>. The helminths were discovered during the autopsy of a wolf (<i>Canis lupus</i> Linnaeus, 1758) killed by hunters in the Kirov oblast in 2021. A molecular phylogenetic study was performed by analyzing the sequence of a fragment of the first subunit of the mitochondrial cytochrome oxidase gene (<i>Cox</i>I). It was found that the detected echinococci belong to the G10 genotype of <i>E. canadensis</i>, which is common in wolves in the northern territories of the Holarctic. We discovered four positions at which the substitutions characteristic only of this genotype are revealed. A substitution at one of the positions that is characteristic exclusively for the representatives of the G10 genotype found in Russia and Finland was also discovered.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141490398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-10DOI: 10.1134/S1607672924700893
L.V. Kondratyeva, Yu. N. Gorbunova, T. A. Panafidina, T. V. Popkova
The objective of the study was to identify different phenotypes of overweight in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) based on body mass index (BMI) and serum leptin levels, as well as to determine the frequencies of various metabolic disorders, hypertension, and cardiovascular complications (CVCs) in individual phenotypes. The study included 50 women with RA and 46 with SLE aged 18 to 65 years without a history of diabetes and fasting hyperglycemia. In all patients, the concentration of leptin was determined by ELISA, the concentration of insulin was determined by electrochemiluminescence analysis, and the HOMA-IR index was calculated. Hyperleptinemia was diagnosed at leptin concentrations > 11.1 ng/mL; insulin resistance (IR), at HOMA-IR values ≥ 2.77. Three main phenotypes of overweight were distinguished: “classic” (BMI ≥ 25 kg/m2 + hyperleptinemia), “healthy” (BMI ≥ 25 kg/m2, without hyperleptinemia), “hidden” or “latent” (BMI < 25 kg/m2 + hyperleptinemia), as well as “normal weight” (BMI < 25 kg/m2, without hyperleptinemia). Patients with RA and SLE were similar in age (p = 0.4), disease duration (p = 0.2) and BMI (p = 0.5). Hyperleptinemia was found in 46% of women with RA and in 74% of women with SLE (p = 0.005), and IR was found in 10 and 22% of patients, respectively (p = 0.2). The “classic” phenotype of overweight was diagnosed in 30%, “healthy” in 8%, and “hidden” in 16% of cases with RA and in 44%, 0%, and 30% of cases with SLE, respectively. IR was found in 3% and hypertension in 6% of patients with “normal weight.” With the “classic” phenotype, IR (29%) and hypertension (66%) were more common than with “normal weight” (p < 0.01 in all cases); with the “hidden” phenotype, significant differences were obtained only in hypertension frequency (45%; p = 0.0012), but not IR (18%). Three out of four women with a history of cardiovascular complications suffered from “classic” overweight, and one patient had a “normal weight.” In women with SLE up to 65 years of age, the frequency of hyperleptinemia, but not IR, is higher than in patients with RA. In both diseases, the “classic” overweight phenotype is most common. In RA, a “hidden” phenotype was detected less often than in SLE, at the same time, a “healthy” phenotype is not characteristic of SLE. The frequency of metabolic disorders and hypertension is low with the “normal weight” and “healthy” phenotype, high with the “classic” phenotype, and intermediate with the “hidden” phenotype.
{"title":"Hyperleptinemia as a Marker of Various Phenotypes of Obesity and Overweight in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus","authors":"L.V. Kondratyeva, Yu. N. Gorbunova, T. A. Panafidina, T. V. Popkova","doi":"10.1134/S1607672924700893","DOIUrl":"10.1134/S1607672924700893","url":null,"abstract":"<p>The objective of the study was to identify different phenotypes of overweight in women with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) based on body mass index (BMI) and serum leptin levels, as well as to determine the frequencies of various metabolic disorders, hypertension, and cardiovascular complications (CVCs) in individual phenotypes. The study included 50 women with RA and 46 with SLE aged 18 to 65 years without a history of diabetes and fasting hyperglycemia. In all patients, the concentration of leptin was determined by ELISA, the concentration of insulin was determined by electrochemiluminescence analysis, and the HOMA-IR index was calculated. Hyperleptinemia was diagnosed at leptin concentrations > 11.1 ng/mL; insulin resistance (IR), at HOMA-IR values ≥ 2.77. Three main phenotypes of overweight were distinguished: “classic” (BMI ≥ 25 kg/m<sup>2</sup> + hyperleptinemia), “healthy” (BMI ≥ 25 kg/m<sup>2</sup>, without hyperleptinemia), “hidden” or “latent” (BMI < 25 kg/m<sup>2</sup> + hyperleptinemia), as well as “normal weight” (BMI < 25 kg/m<sup>2</sup>, without hyperleptinemia). Patients with RA and SLE were similar in age (<i>p</i> = 0.4), disease duration (<i>p</i> = 0.2) and BMI (<i>p</i> = 0.5). Hyperleptinemia was found in 46% of women with RA and in 74% of women with SLE (<i>p</i> = 0.005), and IR was found in 10 and 22% of patients, respectively (<i>p</i> = 0.2). The “classic” phenotype of overweight was diagnosed in 30%, “healthy” in 8%, and “hidden” in 16% of cases with RA and in 44%, 0%, and 30% of cases with SLE, respectively. IR was found in 3% and hypertension in 6% of patients with “normal weight.” With the “classic” phenotype, IR (29%) and hypertension (66%) were more common than with “normal weight” (<i>p</i> < 0.01 in all cases); with the “hidden” phenotype, significant differences were obtained only in hypertension frequency (45%; <i>p</i> = 0.0012), but not IR (18%). Three out of four women with a history of cardiovascular complications suffered from “classic” overweight, and one patient had a “normal weight.” In women with SLE up to 65 years of age, the frequency of hyperleptinemia, but not IR, is higher than in patients with RA. In both diseases, the “classic” overweight phenotype is most common. In RA, a “hidden” phenotype was detected less often than in SLE, at the same time, a “healthy” phenotype is not characteristic of SLE. The frequency of metabolic disorders and hypertension is low with the “normal weight” and “healthy” phenotype, high with the “classic” phenotype, and intermediate with the “hidden” phenotype.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-06-10DOI: 10.1134/S1607672924700868
A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova
Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), p = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), p = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), p = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), p = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.
生物改良抗风湿药(bDMARDs)对强直性脊柱炎(AS)的各种临床表现有不同的影响。有关白细胞介素17抑制剂(IL17-i)对强直性脊柱炎葡萄膜炎影响的数据仍在不断积累。目的:评估IL17-i疗法对强直性脊柱炎葡萄膜炎病程的影响。研究涉及73名强直性脊柱炎患者(纽约标准,1984年),他们接受IL17-i(57-secukinumab (SEC),22-netakimab (NTK))治疗至少1年。患者纳入研究时的平均年龄为(41.93±8.95)岁,强直性脊柱炎的平均病程为(10.75±6.22)年。患者中有 40 名男性(56.7%)和 33 名女性(43.3%)。62/73(85%)例患者检测到 HLA-B27,58(79%)例患者患有髋关节炎,63(86.3%)例患者患有腱鞘炎,57(78%)例患者患有外周关节炎,7(9.5%)例患者患有银屑病,3(4.1%)例患者患有炎症性肠病(IBD);6(8.2%)例患者在 16 岁前开始患病;19(26%)例患者在患病期间至少发作过一次葡萄膜炎。葡萄膜炎的发病率是通过比较开始使用 bDMARDs 治疗前和使用 IL17-i 期间每 100 患者年的发病次数估算得出的。在开始使用bDMARDs治疗前,所有患者的葡萄膜炎发病率为每100 pt-年8.3例(95% CI 0.065-0.107),在使用IL17-i治疗期间为每100 pt-年9.2例(95% CI 0.06-0.15),P = 0.72。在开始使用bDMARDs治疗前,使用SEC的患者葡萄膜炎发病率为每100 pt-年10.1例(95% CI 0.079-0.13),在SEC治疗期间为每100 pt-年9.4例(95% CI 0.05-0.15),P = 0.74。使用NTK的患者葡萄膜炎发病率在开始使用bDMARDs治疗前为每100 pt-年4.8例(95% CI 0.028-0.08),在NTK治疗期间为每100 pt-年7.1例(95% CI 0.019-022),p = 0.3。对于有葡萄膜炎病史的患者,在开始使用bDMARDs治疗前,葡萄膜炎的发生率为每100 pt-年22.5例(95% CI 0.18-0.28),在IL17-i治疗期间,葡萄膜炎的发生率为每100 pt-年29.1例(95% CI 0.18-0.43),p = 0.29。在 SEC 治疗期间,57 例患者中有 4 例(7%)出现葡萄膜炎;在 NTK 治疗期间,25 例患者中有 1 例(4%)出现葡萄膜炎。在使用 SEC 治疗期间,记录到一例新发葡萄膜炎。与非生物疗法相比,IL17-i疗法的葡萄膜炎发病率没有明显差异。在研究组中,IL17-i疗法对强直性脊柱炎葡萄膜炎的病程没有明显影响。
{"title":"Course of Uveitis in Patients with Ankylosing Spondylitis during the Interleukin17 Inhibitors Therapy","authors":"A. A. Godzenko, E. M. Agafonova, A. E. Dimitreva, I. Yu. Razumova, M. M. Urumova","doi":"10.1134/S1607672924700868","DOIUrl":"10.1134/S1607672924700868","url":null,"abstract":"<p>Biological disease-modifying antirheumatic drugs (bDMARDs) can have different effects on various clinical manifestations of ankylosing spondylitis (AS). Data on the effects of interleukin 17 inhibitors (IL17-i) on uveitis in AS continue to accumulate. Objective: to evaluate the effect of IL17-i therapy on the course of uveitis in AS. The study involved 73 patients with AS (New York criteria, 1984), who received IL17-i (57—secukinumab (SEC), 22—netakimab (NTK)) for at least 1 year. The average age of patients at the time of inclusion in the study was 41.93 ± 8.95 years, the average duration of AS was 10.75 ± 6.22 years. There were 40 men (56.7%) and 33 women (43.3%) among the patients. HLA-B27 was detected in 62/73 (85%), coxitis in 58 (79%), enthesitis in 63 (86.3%), peripheral arthritis in 57 (78%), psoriasis in 7 (9.5%), and inflammatory bowel disease (IBD) in 3 (4.1%) patients; in 6 (8.2%) patients, the disease started before the age of 16; 19 (26%) patients had at least one episode of uveitis during the course of the disease. The rates of uveitis was estimated by comparing the number of incidences per 100 patient-years before the start of bDMARDs therapy and during IL17-i using. The incidence rate of uveitis before the start of bDMARDs therapy for all patients was 8.3 per 100 pt-years (95% CI 0.065–0.107), during IL17-i therapy— 9.2 per 100 pt-years (95% CI 0.06–0.15), <i>p</i> = 0.72. The incidence rate of uveitis among patients who used SEC was 10.1 per 100 pt-years (95% CI 0.079–0.13) before the start of bDMARDs therapy and 9.4 per 100 pt-years (95% CI 0.05-0.15), <i>p</i> = 0.74 during SEC therapy. The incidence rate of uveitis among patients who used NTK was 4.8 per 100 pt-years (95% CI 0.028–0.08) before the start of bDMARDs therapy and 7.1 per 100 pt-years (95% CI 0.019–022), <i>p</i> = 0.3 during the NTK therapy. For patients with a history of uveitis, the incidence rate of uveitis was 22.5 per 100 pt-years (95% CI 0.18–0.28) before the start of therapy with bDMARDs and 29.1 per 100 pt-years (95% CI 0.18–0.43), <i>p</i> = 0.29 during IL17-i therapy. Occurrences of uveitis were observed in 4 of 57 patients (7%) during SEC therapy and in 1 of 25 (4%) patients during the NTK therapy. One case of new-onset uveitis was recorded during the using of SEC. There were no significant differences in the incidence rates of uveitis during IL17-i therapy compared with non-biological therapy. IL17-i therapy have not demonstrated a significant effect on the course of uveitis in AS in the study group.</p>","PeriodicalId":529,"journal":{"name":"Doklady Biochemistry and Biophysics","volume":null,"pages":null},"PeriodicalIF":0.8,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}